Anti-PD-L1, Human IgG1 Antibody (Dv3)

Biosimilar to Durvalumab, monoclonal antibody that targets PD-L1
Catalog #: A2109 | abID:

Product Details

Cat # +Size A2109-100
Size 100 μg
Antibody Target PD-L1
Alternate Name PDL1, PD-L1, PD L1, B7-H, B7H1, B7-H1, CD274, PDCD1L1, B7 homolog 1, PDCD1 ligand 1, programmed cell death 1 ligand 1, Programmed death ligand 1
Host CHO cells
Antibody Type Monoclonal
Isotype Human IgG1, kappa
Immunogen Human PD-L1
Accession # DB11714
Appearance Colorless liquid
Formulation In PBS buffer, pH 7.2
Application HTRF assay
Application & Usage HTRF assay
Handling The antibody solution should be gently mixed before use.
Storage Conditions 4°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


The research-grade biosimilar is a human IgG1 monoclonal antibody that is produced by recombinant DNA technology in CHO cells to target programmed cell death-ligand 1 (PD-L1). PD-L1 is an immune inhibitory receptor ligand that is expressed by T and B lymphocytes, as well as various types of tumor cells to escape immune surveillance. Binding of PDL1 to the PD-1 and B7.1 receptors occurs on T cells and antigen-presenting cells that results in suppression of cytotoxic T-cell activity, T-cell proliferation, and cytokine production. During infection or inflammation, PD-L1 plays a role in preventing autoimmunity by maintaining homeostasis of the immune response.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.